Aripiprazole in Children With Autism: A Pilot Study

• Status: Completed
• Trial end date: 2011-11-16
• Target enrollment: 0
• Participant gender: All

Summary

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism.

Children who qualify for the study will be treated with aripiprazole for 6 weeks.

Treatment is provided at no cost.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Drexel University College of Medicine
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.

• Males and females.

• Aged 12 to 18 years.

• Clinical judgment that medication treatment for autism is indicated.

Exclusion Criteria:

• Major medical problems including cardiac, liver, endocrine, or renal diseases.

• Uncontrolled seizures.

• Baseline QTC greater than 425 msec.

• Concomitant treatment with psychotropic medication.

• History of prior exposure to aripiprazole.